AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. ( (ANTX) ) has shared an update.

On March 8, 2026, AN2 Therapeutics entered into a securities purchase agreement for a private placement of 8,245,611 common shares and pre-funded warrants for up to 5,789,493 additional shares, priced at about $2.85 each. The transaction, which is expected to close on March 10, 2026, is set to raise approximately $40 million in gross proceeds from institutional investors including Coastlands Capital, Commodore Capital and Vivo Capital.

The pre-funded warrants carry a de minimis exercise price, no expiration until fully exercised and ownership caps of generally 9.99%, with potential increases subject to Nasdaq rules. AN2 agreed to filing resale registration for the new shares and warrant shares, while accepting short-term restrictions on issuing additional equity, a structure that bolsters its capital position but also dilutes existing shareholders and signals ongoing funding needs typical for clinical-stage biopharmaceutical companies.

The most recent analyst rating on (ANTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on AN2 Therapeutics, Inc. stock, see the ANTX Stock Forecast page.

Spark’s Take on ANTX Stock

According to Spark, TipRanks’ AI Analyst, ANTX is a Neutral.

The score is primarily held back by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a low-debt balance sheet and improving burn trends. Technicals are constructive with the stock trading above major moving averages and a positive MACD, but valuation remains constrained by negative earnings and no dividend yield support.

To see Spark’s full report on ANTX stock, click here.

More about AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. The company’s pipeline includes boron-based compounds targeting polycythemia vera, nontuberculous mycobacterial lung disease caused by M. abscessus, Chagas disease and melioidosis, with additional research programs in oncology and infectious diseases.

AN2 focuses on high-impact drugs addressing critical unmet medical needs and aims to improve health outcomes across infectious disease and oncology indications. Its strategy centers on leveraging proprietary boron chemistry to create differentiated treatments that can capture niche but clinically significant markets in both rare and serious conditions.

Average Trading Volume: 1,216,896

Technical Sentiment Signal: Buy

Current Market Cap: $143.9M

For an in-depth examination of ANTX stock, go to TipRanks’ Overview page.